Market Cap: $67.96B
Market Cap: $67.96B
Takeda Pharmaceutical Company (Ticker: TAK) continues to demonstrate robust financial health in the competitive pharmaceutical market, despite facing challenges from generic competition that affects i…
Eli Lilly's Strategic Expansion in Neuroscience: Implications for the Competitive Landscape Eli Lilly and Company takes a significant step in the neuroscience space with its recent announcement to acq…
Takeda Pharmaceutical Company Targets Innovations in Mental Health Treatments In a landscape where mental health disorders impact over 970 million individuals globally, Takeda Pharmaceutical Company r…
Innovative Serotonergic Therapies on the Rise in Mental Health Treatment Helus Pharma is making significant strides in the booming mental health therapeutics market, which is set to surpass $40 billio…
Takeda’s late‑stage win for Entyvio reshapes its gastroenterology strategy Takeda Pharmaceutical is presenting positive Phase 3 results for its biologic Entyvio in a late‑stage clinical study, a devel…
Takeda’s late‑stage win reported for Entyvio Takeda Pharmaceutical Co Ltd is reporting positive Phase 3 results for Entyvio in a late‑stage clinical study, a development that strengthens the evidence…
Subcutaneous push reshapes Takeda’s biologics strategy Takeda and other large drugmakers are reassessing delivery strategies as the industry shifts toward subcutaneous administration of antibody thera…
Takeda Weighs the Shift to Subcutaneous Delivery Partnerships Takeda Pharmaceutical Company faces a strategic decision as the pharmaceutical industry increasingly adopts enzyme‑mediated subcutaneous d…
Serotonergic agonists reshape big‑pharma CNS strategy Takeda Pharmaceutical and other large drugmakers are closely watching the rise of novel serotonergic agonists (NSAs) as a new class of central ner…
Takeda narrows focus on serotonergic agonists to refresh CNS pipeline Takeda Pharmaceutical Company is among a group of major drugmakers that are actively pursuing novel serotonergic agonists (NSAs) a…
Takeda Pharmaceutical Company Joins BaseLaunch: A Strategic Move to Boost Biotech Innovation Takeda Pharmaceutical Company strengthens its commitment to biotechnology innovation by officially joining…
Takeda Pharmaceutical Company Strengthens Biotech Ties Through BaseLaunch Partnership Takeda Pharmaceutical Company has made a significant move in the biotech landscape by officially joining BaseLaunc…
Innovative Collaboration: Takeda and Innovent Biologics Team Up in Immuno-Oncology In a significant advancement in cancer treatment, Takeda Pharmaceutical Company has successfully closed a strategic c…
Takeda and Innovent Forge Strategic Alliance to Advance Cancer Therapies In a significant development within the biopharmaceutical sector, Takeda Pharmaceutical Company has finalized a strategic colla…
Adzynma's Safety Concerns Prompt FDA Vigilance The recent reports from the U.S. Food and Drug Administration (FDA) regarding Takeda Pharmaceutical Company's recombinant ADAMTS13 product, Adzynma, rais…
Takeda Pharmaceutical: Driving Innovation Amid Market Challenges Takeda Pharmaceutical Company stands at the forefront of biotechnology and pharmaceuticals, focusing on innovative treatments that addr…
Takeda Pharmaceutical's Focus on Strategic Growth Amid Industry Challenges Takeda Pharmaceutical Company continues to navigate the complexities of the global healthcare landscape, with a keen emphasis…
Takeda Partners with TetraScience to Revolutionize Biopharmaceutical R&D On October 24, 2025, Takeda Pharmaceutical Company joins forces with TetraScience, a leading scientific data and AI company, as…
Takeda Pharmaceutical Partners with TetraScience to Drive Innovation in Drug Development In a significant collaboration, Takeda Pharmaceutical Company teams up with TetraScience, a leader in scientifi…
Takeda and Innovent Forge Strategic Alliance to Advance Immuno-Oncology Therapies In a significant development within the biopharmaceutical sector, Takeda Pharmaceutical Company and Innovent Biologics…
### Takeda Pharmaceutical Company Strengthens Position in Cancer Treatment Through Strategic Collaboration Takeda Pharmaceutical Company embarks on a transformative partnership with Innovent Biologics…
Nabla Bio and Takeda Forge Strategic Partnership to Enhance Drug Discovery In a significant development within the biotechnology sector, Nabla Bio has entered into a multi-year research collaboration…
Takeda Pharmaceutical Faces Competitive Landscape Amid Industry Consolidation In light of ongoing negotiations between Johnson & Johnson and Protagonist Therapeutics, Takeda Pharmaceutical Company fin…
TAK Broadband Expands Southern California Presence with GSI Acquisition In a strategic move to bolster its operations in California, TAK Broadband has announced the acquisition of Gulbranson Services,…
TAK Broadband Strengthens Market Position with Strategic Acquisition TAK Broadband, a national provider of fiber and broadband network services, announces its acquisition of Gulbranson Services, Inc.…
Takeda Pharmaceutical Company Commits to Enhancing Maternal and Child Nutrition in Indonesia Takeda Pharmaceutical Company Limited takes a significant step in global health by funding the Climate-Insp…
Takeda Pharmaceutical Company Backs Climate-Inspired Nutrition Initiative in Indonesia In a significant move towards addressing maternal and child health challenges exacerbated by climate change, Take…
Navigating Market Dynamics: Takeda's Strategic Position in the Pharmaceutical Landscape Takeda Pharmaceutical Company finds itself at a crucial juncture as it navigates the complexities of the pharmac…
Innovative Treatment for Hereditary Angioedema: A New Era for Patient Care Ionis Pharmaceuticals, Inc. achieves a significant milestone with the recent approval by the U.S. Food and Drug Administratio…
FDA Approval of IONS Dawnzera: A New Era for Hereditary Angioedema Treatment In a significant advancement for the treatment of hereditary angioedema (HAE), the U.S. Food and Drug Administration (FDA)…
Takeda Pharmaceutical's Strong First-Quarter Performance Reflects Strategic Success Takeda Pharmaceutical Company Limited announces a remarkable first-quarter performance for 2025, reporting a net pro…
Takeda Pharmaceutical Company: Navigating Challenges and Capitalizing on Growth As Takeda Pharmaceutical Company prepares to announce its quarterly earnings on July 30, 2025, stakeholders are keenly f…
Legal Landmark for Takeda: RICO Class Action Advances The U.S. Court of Appeals for the Ninth Circuit has recently upheld a pivotal class certification order in the ongoing case of Painters & Allied T…
Legal Milestone for Takeda as Ninth Circuit Upholds Class Certification in RICO Case In a landmark decision, the U.S. Court of Appeals for the Ninth Circuit affirms a critical class certification orde…
Shifting Perspectives in Biotech: Keros Therapeutics Faces Downgrade Amid Market Reevaluation Recent developments in the biotech sector underscore the volatility and competitive nature of the industry…
Takeda’s Fiscal Challenges and Future Strategies Amidst Declining Profit Takeda Pharmaceutical Company Limited faces significant headwinds as it announces a steep decline in its net profit for fiscal…
Takeda Faces Profitability Challenges Amid Market Pressures Takeda Pharmaceutical Company Limited confronts significant challenges in the current pharmaceutical landscape, as evidenced by its recent f…
### Strengthening Vaccine Distribution: Novavax and Takeda's Enhanced Collaboration Novavax, Inc. announces a significant improvement in its collaboration and licensing agreement (CLA) with Takeda Pha…
Strengthening Ties: Novavax and Takeda’s Enhanced Collaboration on COVID-19 Vaccine Novavax, Inc. solidifies its strategic partnership with Takeda Pharmaceutical Company through a recently amended col…
Novavax and Takeda Strengthen Partnership for COVID-19 Vaccine in Japan Novavax, Inc. enhances its collaboration with Takeda Pharmaceutical Company, focusing on the Japanese market for its COVID-19 va…
Takeda’s Strategic Partnership Marks a Milestone in Gene Therapy for Hemophilia B In a significant advancement for patients suffering from moderate to severe hemophilia B, Takeda Pharmaceutical Compan…
Takeda Partners with BridGene to Innovate Drug Discovery in Immunology and Neurology In a significant strategic collaboration announced on February 25, 2025, Takeda Pharmaceutical Company teams up wit…
Takeda Expands Treatment Options for Hereditary Angioedema with New Pre-Filled Pen Approval Takeda Pharmaceutical Company announces that the European Medicines Agency (EMA) has approved a new 2 mL pre…
Takeda Pharmaceutical Appoints Julie Kim as Future CEO Amid Strategic Growth Plans Takeda Pharmaceutical Company, a prominent player in the global biopharmaceutical industry, announces the appointment…
Takeda Pharmaceutical Company Appoints New CEO to Propel Future Growth Takeda Pharmaceutical Company announces a pivotal leadership transition with the appointment of Julie Kim as the next CEO, succee…
Takeda Pharmaceutical Secures Approval for Innovative Immunotherapy in Japan Takeda Pharmaceutical Company achieves a significant milestone with the recent approval of HYQVIA® by the Japanese Ministry…
Takeda's Innovative Breakthrough: Approval of HYQVIA® in Japan Takeda Pharmaceutical Company announces a significant milestone with the approval of HYQVIA® (Immune Globulin Infusion 10% with Recombina…
Axcelead DDP Partners with Astellas Pharma to Advance Drug Discovery Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) recently enters into a significant drug discovery service agreement with Aste…
Takeda Pharmaceutical Company Advances Innovative Pipeline to Transform Patient Care Takeda Pharmaceutical Company, a global leader in the biopharmaceutical industry, is actively shaping the future of…
Takeda and Keros Therapeutics Forge Exclusive Partnership for Anemia Treatment Takeda Pharmaceutical Company Limited has solidified its commitment to advancing oncology treatments through a recent exc…